Detection rate and characteristics of heart failure, depending on the diagnostic criteria in COVID-19 survivors one year after hospitalization

Detection rate and characteristics of heart failure, depending on the diagnostic criteria in COVID-19 survivors one year after hospitalization

Aim. To estimate the detection rate of heart failure (HF), using various diagnosis criteria, among patients aftr 12 months after hospital treatment for coronavirus disease 2019 (COVID-19).Material and methods. The study included 185 patients from the TARGET-VIP registry who came for a visit 12 month...

Full description

Bibliographic Details
Main Authors:	Yu. V. Mareev, M. M. Lukyanov, S. Yu. Martsevich, A. A. Pulin, N. P. Kutishenko, E. Yu. Andreenko, V. P. Voronina, V. A. Dindikova, N. A. Dmitrieva, A. N. Makoveeva, O. V. Lerman, E. Yu. Okshina, A. A. Smirnov, M. M. Kudryavtseva, E. N. Belova, V. G. Klyashtorny, E. V. Kudryashov, O. E. Karpov, O. M. Drapkina
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2023-01-01
Series:	Кардиоваскулярная терапия и профилактика
Subjects:	хроническая сердечная недостаточность хроническая сердечная недостаточность с сохраненной фракцией выброса левого желудочка covid-19 шкала h2fpef мозговой натрийуретический пропептид
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/3437

Similar Items

NEW EMPHASES ON THE STUDY OF THE PATHOGENESIS OF CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION: FOCUS ON INFLAMMATORY MARKERS
by: O. M. Drapkina, et al.
Published: (2015-09-01)

The relationship between gut microbiota, chronic systemic inflammation, and endotoxemia in patients with heart failure with preserved ejection fraction
by: A. N. Kaburova, et al.
Published: (2022-10-01)

Relationship between gut microbiota and markers of myocardial fibrosis in with chronic heart failure with preserved ejection fraction
by: A. N. Kaburova, et al.
Published: (2021-07-01)

THE ROLE OF DIET AND PHYSICAL ACTIVITY IN THERAPY OF CARDIOVASCULAR PATIENTS WITH NORMAL EJECTION FRACTION
by: O. M. Drapkina, et al.
Published: (2017-04-01)

Effect of therapy on the dynamics of collagen metabolism markers in older patients with heart failure with mid-range ejection fraction and coronary artery disease
by: O. A. Osipova, et al.
Published: (2020-11-01)

Predictors of an adverse course of heart failure with preserved left ventricular ejection fraction in patients with obstructive sleep apnea syndrome
by: A. T. Teplyakov, et al.
Published: (2021-07-01)

Positive effect of if-channel’s blocker ivabradine therapy in a patient with ischemic chronic heart failure with preserved left ventricle ejection fraction and hereditary thrombophilia (clinical case)
by: Iurii N. Belenkov, et al.
Published: (2019-09-01)

НОВЫЕ АСПЕКТЫ ПАТОГЕНЕЗА И ДИАГНОСТИКИ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ С СОХРАНЁННОЙ ФРАКЦИЕЙ ВЫБРОСА В СОЧЕТАНИИ С САХАРНЫМ ДИАБЕТОМ 2 ТИПА
by: А. А. Снеткова, et al.
Published: (2014-04-01)

NEW POSSIBILITIES FOR EVALUATION OF SEVERITY AND PROGNOSIS IN PATIENTS WITH CHRONIC HEART FAILURE BASED ON N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE PLASMA LEVEL
by: A. S. Galjavich, et al.
Published: (2016-01-01)

CLINICAL FEATURES OF HEART FAILURE WITH LOW EJECTION FRACTION COMBINED WITH ANEMIA
by: Konstantin Viktorovich Protasov, et al.
Published: (2023-09-01)

NEW OPPORTUNITIES IN TREATMENT OF CHRONIC HEART FAILURE WITH NORMAL EJECTION FRACTION
by: A. G. Dushina, et al.
Published: (2015-08-01)

Novel algorithms for diagnosing heart failure with preserved ejection fraction in patients with hypertension and obesity
by: Yu. A. Vasyuk, et al.
Published: (2021-02-01)

Features of cardiovascular remodeling, the level of neurohumoral factors depending on the degree of chronic heart failure and kidney dysfunction
by: U. K. Kamilova, et al.
Published: (2019-06-01)

Pathogenesis of chronic heart failure: change of dominating paradigm
by: V. V. Kalyuzhin, et al.
Published: (2007-12-01)

CHRONIC HEART FAILURE AND IRON-DEFICIENT ANEMIA
by: M. V. Melnik, et al.
Published: (2015-12-01)

Cardiac Amyloidosis: Internist and Cardiologist Insight
by: E. V. Reznik, et al.
Published: (2020-12-01)

KEY PATHOGENETIC ASPECTS AND CLINICAL RELEVANCE OF MECHANICAL DYSSYNCHRONY
by: Yu. V. Stavtseva, et al.
Published: (2015-09-01)

NEW OPPORTUNITIES FOR PREVENTIVE THERAPY WITH STATINS DURING CHD PATIENTS’ REHABILITATION, WITH CLINICAL SIGNS OF MODERATE CHF: EFFECTIVENESS OF ROSUVASTATIN AND EZETIMIBE
by: N. I. Tarasov, et al.
Published: (2016-06-01)

Atrial Fibrillation and Heart Failure as the Onset of AL-Amyloidosis
by: E. V. Reznik, et al.
Published: (2021-11-01)

Spirapril – a modern ACE inhibitor
by: V. M. Gorbunov
Published: (2005-06-01)

Echocardiographic characteristics of patients with ischemic and non-ischemic chronic heart failure with reduced ejection fraction
by: N. N. Ilov, et al.
Published: (2022-10-01)

EFFECT OF MITRAL REGURGITATION ON CHRONIC HEART FAILURE COURSE AND STRUCTURE-FUNCTIONAL HEART STATE
by: V. N. Larina, et al.
Published: (2016-01-01)

The role of cardiomyocyte apoptosis in mechanisms of ischemic myocardial remodeling
by: A. P. Khlapov, et al.
Published: (2008-09-01)

Differential beta-adrenoblocker therapy in chronic heart failure
by: S. N. Tereshchenko, et al.
Published: (1970-01-01)

Natriuretic peptide family. Options for use in outpatient practice
by: S. V. Ivanova, et al.
Published: (2014-12-01)

Modern echocardiographic criteria for heart failure with preserved ejection fraction: not only diastolic dysfunction
by: O. M. Drapkina, et al.
Published: (2020-04-01)

Russian National Research Medical University named after N.I. Pirogov, Moscow
by: V. N. Larina, et al.
Published: (2015-09-01)

ВЛИЯНИЕ АПОПТОЗА НА ТЕЧЕНИЕ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ
by: Ye. N. Berezikova, et al.
Published: (2015-10-01)

CHANGES IN CLINICAL MANIFESTATION OF CONGESTIVE HEART FAILURE AT THE BACKGROUND OF REGULAR RAMIPRIL INTAKE
by: A. G. Kuzmin, et al.
Published: (2014-08-01)

Bisoprolol and sotalol for maintaining sinus rhythm in patients with paroxysmal atrial fibrillation and chronic heart failure
by: S. N. Tereshchenko, et al.
Published: (2005-12-01)

Selective beta-blocker bisoprolol: effectiveness and safety in complex treatment of patients with chronic heart failure and Type 2 diabetes mellitus. RAMBO-DM CHF Study results
by: Yu. V. Lapina, et al.
Published: (2008-08-01)

SELECTION OF THE OPTIMAL ANTIHYPERTENSION TREATMENT IN PATIENTS WITH CHRONIC HEART FAILURE WITH THE SIGNS OF CHRONIC KIDNEY DISEASE
by: N. Yu Borovkova, et al.
Published: (2016-12-01)

Prevention of atrial fibrillation episodes in patients with chronic heart failure: a new approach to the old problem
by: Yu. M. Pozdnyakov, et al.
Published: (1970-01-01)

Differential beta-adrenoblocker therapy in chronic heart failure: the role of age, gender, and co-morbidity
by: S. N. Tereshchenko, et al.
Published: (2009-10-01)

Physical training – modulator of peripheral factors for chronic heart failure development
by: A. S. Noskova, et al.
Published: (2007-02-01)

ROLE OF THE METABOLITE THERAPY FOR THE TREATMENT OF CHRONIC HEART FAILURE
by: L. N. Maksimova, et al.
Published: (2015-09-01)

Beta-adrenoblocker in heart failure: bisoprolol role
by: Yu. V. Lukina, et al.
Published: (1970-01-01)

Hypertensive encephalopathy, heart remodeling, and chronic heart failure
by: L. A. Geraskina, et al.
Published: (2006-06-01)

HEART RATE-LOWERING THERAPY IN THE TREATMENT OF CHRONIC HEART FAILURE
by: S. V. Shalaev, et al.
Published: (2015-09-01)

Modern concept of diastolic heart failure
by: F. T. Ageev
Published: (1970-01-01)